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Abstract
Objective: Transcription factor forkhead box protein 3 (Foxp3) specifically characterizes the
thymically derived naturally occurring regulatory T cells (Tregs). Limited evidence indicates that it
is also expressed, albeit to a lesser extent, in tissues other than thymus and spleen, while, very
recently, it was shown that Foxp3 is expressed by pancreatic carcinoma. This study was scheduled
to investigate whether expression of Foxp3 transcripts and mature protein occurs constitutively in
various tumor types.
Materials and methods: Twenty five tumor cell lines of different tissue origins (lung cancer,
colon cancer, breast cancer, melanoma, erythroid leukemia, acute T-cell leukemia) were studied.
Detection of Foxp3 mRNA was performed using both conventional RT-PCR and quantitative real-
time PCR while protein expression was assessed by immunocytochemistry and flow cytometry,
using different antibody clones.
Results: Foxp3 mRNA as well as Foxp3 protein was detected in all tumor cell lines, albeit in
variable levels, not related to the tissue of origin. This expression correlated with the expression
levels of IL-10 and TGFb1.
Conclusion: We offer evidence that Foxp3 expression, characterizes tumor cells of various tissue
origins. The biological significance of these findings warrants further investigation in the context of
tumor immune escape, and especially under the light of current anti-cancer efforts interfering with
Foxp3 expression.
Background
The transcription factor forkhead box protein 3 (Foxp3) is
considered to be a master control gene of the function of
thymically derived naturally occurring regulatory T cells
(Tregs) [1]. Due to the Tregs lineage specification by
Foxp3, its tissue expression primarily by lymphoid tissues
(thymus, spleen and lymph nodes) is expected and it has
been well documented [1,2]. Despite, however, the scar-
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city of information, Foxp3 expression by other normal tis-
sues has also been observed, albeit to a far lesser extent
[3]. Moreover, induction of Foxp3 expression can occur
intrinsically in peripheral Foxp3- T cells [4], while periph-
eral activated CD4+CD25- and CD8+CD25- T cells can
acquire a regulatory function by expressing Foxp3 [5,6].
Since the factors inducing Foxp3 expression in the above
T cell populations remain unknown, we hypothesized
that a similar induction could take place in other types of
cells such as tumor cells. In support of the above, a very
recent publication describes the expression of Foxp3 in
pancreatic carcinoma cells providing evidence that this
could be an important tumor escape mechanism [7]. To
this end, this study was scheduled to investigate whether
expression of Foxp3 transcripts and mature protein is con-
fined to pancreatic carcinoma or can occur constitutively
in other tumor types as well as whether it might be
repressed as a result of promoter hypermethylation, as is
the case with several other genes including many associ-
ated with a tumor suppressor function [8]. We provide
unequivocal evidence that Foxp3 is expressed both at the




Twenty two tumor cell lines of various tissue origins,
kindly donated by collaborators (Table 1), as well as 3
cancer cell lines recently established, as previously
described [9], from tumor cell suspensions collected from
lung adenocarcinoma patients submitted to surgery
(PGEGE, PKAKI and PINTZ), were studied. All cell lines
were kept frozen and upon thawing they were maintained
in complete medium (CM) that consisted of Iscove's
medium (Gibco Laboratories, Grand Island, NY, USA),
10% FCS (Gibco), 100 μM Minimal Essential Aminoacids
(Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin
(Gibco), 2 mM glutamine (Gibco) and 50 μM 2-mer-
captethanol (Gibco), supplemented with hydrocortisone,
17β-estradiol, sodium selenite, insulin and transferrin
(HITES solution) as described by Carney et al [10], at
37°C in 8% CO2.
To explore whether the expression of Foxp3 by cancer cells
is affected by culture with the HITES solution, experi-
ments were undertaken using parallel cultures of tumor
cell lines, in the presence and in the absence of HITES
solution, i.e. at corticosteroid concentrations used to
inhibit development of lymphocytes, for a period of 3
weeks, allowing at least 10–12 cell divisions. All experi-
ments were repeated three times.
Foxp3 mRNA expression
Foxp3 mRNA expression was examined in all cases using
both conventional PCR (RT-PCR) and quantitative real-
time PCR (qRT-PCR), after total RNA isolation from the
tumor cell lines and reverse transcription to cDNA, as pre-
viously described [11], qRT-PCR was performed using the
automated thermocycler RotorGene 6000 (Corbett Life
Science, Sydney, Australia), the SYBR Supermix kit (Invit-
rogen, Paisley UK) and the RT2 PCR Primer Set for Foxp3
(SuperArray, USA). β2-Microglobulin (β2-M) was used as
a reference gene (RT2  PCR Primer Set, SuperArray)
[12,13]. The qRT-PCR thermocycling conditions for Foxp3
were: 10 min at 95°C initial hold, followed by 40 cycles
of denaturation at 95°C, annealing at 60°C and extension
at 72°C all for 15 sec. The qRT-PCR thermocycling condi-
tions for β2-M were: 10 min at 95°C initial hold, followed
by 40 cycles of denaturation at 95°C for 15 sec, anneal-
ing/extension at 60°C for 60 sec. Relative expression was
analyzed using the Rotor Gene software (Ver. 6) and is
presented as a multiple of the gene expression in one
fibroblast line isolated during the development of the
cancer cell lines. EBV-transformed B cells were used as
negative controls, whereas a CD4+ Treg clone (kindly pro-
vided by Sophie Lucas, Brussels, Belgium) and PHA blasts
were used as positive controls. For RT-PCR amplifications,
20 μM of the following primer sets were used for β-actin,
forward 5' GGCATCGTGATGGACTCCG 3' and reverse 5'
GCTGGAAGGTGGACAGCGA 3' and the RT2 PCR Primer
Set for Foxp3 (SuperArray), in a total reaction volume of
25 μL. Thermocycling conditions (PTC-200, MJ Research,
Watertown-Mass., USA) included for β-actin 21 cycles of
denaturation at 94°C, annealing at 68°C and extension at
72°C, all for 1 min, and for Foxp3, 31 cycles of denatura-
tion at 95°C, annealing at 60°C and extension at 72°C,
all for 15 sec.
IL-10 and TGFb1 mRNA expression
IL-10 and TGFb1 mRNA expression was examined using
both conventional PCR (RT-PCR) for IL-10 and quantita-
tive real-time PCR (qRT-PCR) for TGFb1 using cDNA pre-
pared as above. For TGFb1, the RT2 PCR Primer Set from
SuperArray was used, and the qRT-PCR thermocycling
conditions were: 10 min at 95°C initial hold, followed by
40 cycles of denaturation at 95°C for 15 sec and anneal-
ing/extension at 60°C for 60 sec. β2-M was used as a ref-
erence gene as for Foxp3 and the relative expression was
Table 1: Cancer cell lines used in the study.
Cancer cell lines Type of cancer
CALU-1, CALU-6, GILI, ONET, SK-LU-1, 
NCI-H441, NCI-H460, NCI-H596, NCI-H661, 
NCI-H520, PGEGE, PKAKI, PINTZ
Lung cancer
HCA 2.6, HCA 3.2 Colon cancer
MCF7, T47D, HBL-100p40, BT20, 
MDAMB231
Breast cancer
GERL, DAJU 2.7, MEL272,  Melanoma
K562 Erythroid leukemia
JURKAT Acute T cell 
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analyzed and presented as above. For RT-PCR amplifica-
tions of IL-10, 20 μM of the RT2 PCR Primer Set for IL-10
(SuperArray) was used in a total reaction volume of 25 μL.
Thermocycling conditions included 30 cycles of denatur-
ation at 95°C for 15 sec, annealing at 60°C for 15 sec and
extension at 72°C for 30 sec. IL-10 expression is presented
as a semiquantitative measurement obtained by calculat-
ing the intensity quotient for the gene and β-actin [14]
and then normalizing to that of a fibroblast cell line.
Foxp3 protein expression
To determine whether the expression of Foxp3  mRNA
results in the production of a mature protein, tumor cell
lines were examined by immunohistochemistry and by
flow cytometry for intracellular expression of Foxp3, using
different antibody clones. Immunostaining was per-
formed according to a previously published protocol with
slight modifications [15]. Sections were fixed in 4% para-
formaldehyde, blocked in 5% normal mouse serum (eBi-
oscience), and incubated with a mouse monoclonal
biotinylated anti-Foxp3 antibody against the amino ter-
minus of the human Foxp3 protein (dilution 1/250)
(clone 236A/E7, eBioscience, San Diego, USA), followed
by goat anti-mouse secondary antibody and dextran cou-
pled with peroxidase molecules (EnVision Detection Sys-
tem, Peroxidase/DAB, Rabbit/Mouse, Dako). DAB
(EnVision Detection System, Dako) was used as peroxi-
dase substrate, while endogenous peroxidase activity was
blocked directly after the fixation step with 1% of H2O2 in
1xTBS. Sections were counterstained with Mayer hema-
toxylin (Merck).
Flow cytometric detection of intracellular Foxp3 expres-
sion was performed using an anti-Foxp3 monoclonal anti-
body (clone PCH101, eBioscience) labeled with
phycoerythrin and the corresponding IgG2a isotypic anti-
body according to the manufacturer. In each analysis,
approximately 106 tumor cells were used, and approxi-
mately 50–100 × 103 events were acquired and analyzed
on the basis of Foxp3 positivity using the CXP program
(Beckman Coulter, USA). Positivity was determined on
the basis of the Mean Fluorescence Index (MFI) for stain-
ing with Foxp3, against the staining observed with the cor-
responding isotypic antibody.
Statistical analysis
Expression values are presented as raw values or as mean
± SD. Spearman's bivariate correlation was used to iden-
tify correlations (Pearson's correlation and significance is
presented) with the statistical software SPSS for Windows
(version 11.5).
Results and discussion
Expression of Foxp3 mRNA was revealed in all tumor cell
lines studied (Fig. 1). Relative expression values for tumor
cells varied widely between 0.5 and 260 (17.4 ± 53.4) and
were significantly higher than those of fibroblasts (1.9 ±
1.6) and EBV-transformed B cells (3.5 ± 1.2). This expres-
sion did not relate to the tissue of origin of each line. The
highest expression levels of Foxp3 observed by tumor cells
was with the breast cancer line MCF7 (260), which
expressed at least half as much Foxp3 as the Treg clone
(419) did, and at least ten times more than a population
of PHA blasts (23.5). This expression level indicates that
Foxp3 transcripts are present in a sufficiently high number
in tumor cells and caution should be exerted when detec-
tion of Foxp3 mRNA expression in surgical tumor samples
is used as an index of tumor infiltration by Tregs.
All tumor lines tested, exhibited distinct staining profiles
(Fig. 2). Heterogenous subcellular localization of Foxp3
(predominantly perinuclear cytoplasmic and/or mainly
nuclear) was observed in lines of epithelial as well as of
non-epithelial origin, while EBV-transformed B cells were
devoid of staining. This finding warrants further attention
with respect to the possible functional consequences of
nuclear and/or perinuclear cytoplasmic Foxp3 expression
by cancer cells. In particular, under the light of recent find-
ings revealing the physical interaction of Foxp3 with the
nuclear factor of activated T cells (NFAT), it appears that
at least with respect to its nuclear localization, Foxp3 plays
a pivotal role in the formation of nuclear complexes that
are important to regulate the transcription of several target
genes [16], that confer to Tregs their suppressive function
[17].
Flow cytometric analysis confirmed the results of immu-
nohistochemistry regarding Foxp3 protein expression.
Intracellular Foxp3 was examined in 15 tumor lines, all of
which expressed the protein, whilst none of the EBV-
transformed B cells and fibroblast lines used as controls
displayed any Foxp3 staining (Fig. 3). The mean fluores-
cence intensity (MFI) varied between 2.07 and 13.90
allowing the discrimination of the tumor cells into three
patterns of distinct staining intensity. The first (n = 3),
with an MFI 2.07–2.92, the second (n = 9) with an MFI
3.79–4.87 and the third (n = 3) with an MFI >5. The pro-
tein expression levels related weakly to the Foxp3 mRNA
expression levels.
Corticosteroids significantly increase Foxp3-as well as
IL10- mRNA expression in un-stimulated peripheral
blood CD4+ T cells [18]. No difference in Foxp3 mRNA
expression levels was detected when cancer cell lines (n =
3) were cultured with or without HITES, for a period of 3
weeks (10–12 cell divisions). This difference between can-
cer cells and CD4+ T cells might represent a mechanism
utilized by the first to escape from corticosteroid-regu-
lated death mediated by GITR as it happens in T cells [19].Journal of Translational Medicine 2008, 6:19 http://www.translational-medicine.com/content/6/1/19
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Expression of Foxp3 mRNA in tumor cell lines by qRT-PCR (histograms on the top) and RT-PCR (electrophoretic plots in the  bottom) Figure 1
Expression of Foxp3 mRNA in tumor cell lines by qRT-PCR (histograms on the top) and RT-PCR (electro-
phoretic plots in the bottom).Journal of Translational Medicine 2008, 6:19 http://www.translational-medicine.com/content/6/1/19
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Following the recent finding that Foxp3 is expressed by
pancreatic carcinoma cells [7], our study clearly demon-
strates that its expression is not restricted to this particular
type of tumor but seems to characterize many other
tumors not only of epithelial (e.g. lung, breast, colon) but
also of other tissue origins (melanoma, leukemia).
Whether Foxp3 expression by tumor cells is directly
related to carcinogenesis or results indirectly by activation
of its normally silent gene, is questionable. Fibroblasts
used as controls in our study exhibited insignificant levels
of Foxp3 transcripts that is in accordance to the results of
Hinz et al [7] showing no Foxp3 expression by normal
pancreatic duct epithelial cells. However, Christodoulou
et al [20] have shown that normal salivary gland epithelial
cells express Foxp3 mRNA, as did three neoplastic lines of
epithelial origin, but not human umbilical vein endothe-
Immunohistochemical staining of tumor cell line cytospins Figure 2
Immunohistochemical staining of tumor cell line cytospins. A: Melanoma (GERL); predominant cytoplasmic expres-
sion. B: Lung adenocarcinoma (GILI); cytoplasmic and nuclear expression. C: Colon adenocarcinoma (HCA 2.6); predominant 
cytoplasmic expression. D: T Lymphoblastic leukemia (JURKAT); cytoplasmic and nuclear expression. E: Breast adenocarci-
noma (MCF7); predominant cytoplasmic expression. F: Not expressing EBV-transformed B cells. Inserts represent May-Gru-
vald-Giemsa staining of the corresponding cell lines.Journal of Translational Medicine 2008, 6:19 http://www.translational-medicine.com/content/6/1/19
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lial cells. Foxp3 induction pathways (e.g. those of IFN-γ,
TLRs and others) that, along with the TcR-mediated one,
are functioning in Tregs [21], could be implicated in can-
cer and/or transforming cells. In fact, the recently shown
induction by TGF-β [7] seems to be a key facet of the com-
plex role of TGF-β in cancer biology [22].
The varying levels of Foxp3 mRNA expression detected in
tumor cells raises a serious issue concerning the use of the
detection of Foxp3 mRNA expression in surgical tumor
samples as an index of tumor infiltration by Tregs [23-25].
Thereby, conclusions derived from such studies about the
relationship between Tregs and cancer might be mislead-
ing [26,27]. This variation however, might also imply a
different role for Foxp3 expression by tumor cells. A recent
finding in breast cancer cells proposes Foxp3 as an impor-
tant suppressor for human breast cancer [28]. Functional
somatic mutations, and down-regulation of the FOXP3
gene, were commonly found in human breast cancer sam-
ples and although this also correlated with HER-2/ErbB2
overexpression it was clearly lower than that of normal
breast tissue [28]. Whether the presence of such mutations
could account for the very low expression levels observed
with some tumor lines in our study remains to be investi-
gated as does confirmation that Foxp3 is a tumor suppres-
sor molecule.
In assessing further whether Foxp3 mRNA expression
detected in tumor cells had any putative functional signif-
icance for the tumor cells, we assessed the levels of mRNA
expression for IL-10 and TGFb1 (Fig 4). Both IL-10 (0.7 ±
4.2) and TGFb1 (3.6 ± 4.2) were expressed by nearly all
tumor cells. Interestingly, these expression levels also cor-
related with Foxp3 mRNA expression (Foxp3 vs TGFb1:
Pearson's correlation = 0.74, significance= 0.0001; Foxp3
vs IL-10: Pearson's correlation = 0.529, significance =
0.009; TGFb1 vs IL10: Pearson's correlation = 0.499, sig-
nificance = 0.015). Whether, these relations play any sig-
nificant role in conferring to the tumors the ability to
evade immunity remains to be elucidated.
Based on the finding that Foxp3 expression by pancreatic
carcinoma results in inhibition of proliferation and possi-
bly not of activation of naïve CD4+ CD25- T cells, Hinz et
al [7] propose that this might represent a tumor escape
mechanism. Our results, however, uncovering Foxp3
expression as a generalized feature of tumor cells, indicate
that the determination of its functional consequences
requires further elucidation, especially in the context of
Expression of IL-10 (left) and TGFb1 (right) mRNA in tumor  cell lines Figure 4
Expression of IL-10 (left) and TGFb1 (right) mRNA in 
tumor cell lines.
Flow cytometric detection of Foxp3 expression in various  cell lines Figure 3
Flow cytometric detection of Foxp3 expression in 
various cell lines. (A) negative control (EBV-transformed B 
cells), (B) an erythroid leukemia cell line with low expression, 
and (C+D) breast cancer cell lines with moderate and high 
expression. The white underlaid plot represents staining with 
the isotype.Journal of Translational Medicine 2008, 6:19 http://www.translational-medicine.com/content/6/1/19
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current anti-cancer efforts to control the pathogenetic
action of Tregs, mainly those interfering with Foxp3
expression [29].
Conclusion
This study provides clear evidence that cancer cells of var-
ious types express a transcript for Foxp3 as well as the
mature protein. This finding can be of utmost significance
under the light of Tregs being implicated in carcinogenesis
and ongoing efforts towards the development of antican-
cer approaches specifically inhibiting the expression and/
or function of Foxp3 by tumor-associated Tregs
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